The hum of a refrigerator in a quiet kitchen. That’s where many pharmaceutical ads still live, on screens that rarely shift. For decades, the pharma industry has poured vast sums into television, clinging to its elaborate productions and the predictable cadence of linear broadcasts. But a seismic shift is underway, and if you’re in the adtech world, you’re likely feeling the tremors.
Connected TV (CTV) isn’t just another pipe for eyeballs; it’s a fundamental platform shift, a new operating system for reaching people. Yet, CMI Media Group’s Andrew Miller, EVP of digital activation, feels many pharma brands are still treating it like a side dish instead of the main course. “I honestly don’t think brands are recognizing that enough and I think they need to take more advantage of that and plan,” he told Beet.TV.
The Ancient Economics of Pharma Ads
Think about it: linear TV advertising was built for a different era. Huge budgets, painstakingly long creative development cycles – it was like building a cathedral, magnificent but incredibly slow to adapt. Miller nails it: “Linear budgets tend to be very large. The creative takes a long time to build and create. And then it’s kind of hard to manipulate that in a lot of ways.” CTV, on the other hand, is the agile startup of the advertising world. It offers a level of flexibility that linear simply can’t touch.
This isn’t just about tweaking ad spend mid-campaign; it’s about creative agility. Gone are the days of rigid format specs and expensive, actor-laden shoots for every permutation. Miller explains, “You can have a 90 second spot, a 60 second spot, a 15 second spot, you can chop it up.” This freedom means animation, shorter-form content, and a wider array of messaging strategies are not just possible, but practical. It’s like going from a black-and-white film reel to a dynamic, interactive digital canvas.
Where the ‘Halo Effect’ Shines Brightest
This is the real kicker, the part that has my futurist heart soaring. Miller calls it the “halo effect” – the often-unseen influence a CTV campaign has on other marketing channels. When a pharma brand runs a compelling CTV campaign, it doesn’t just get clicks on a streaming service. It ignites conversations, drives search queries, and boosts social media engagement. It’s a ripple effect, radiating outwards, influencing the entire customer journey.
And here’s where the skepticism kicks in – many brands, Miller observes, are failing to even look for this halo. They’re so focused on the immediate metrics of the CTV buy itself that they’re missing the broader impact. “What’s happening? Are you seeing an increase in search? Are you seeing an increase in social presence? And then what do you do for your omnichannel strategy in response to that?” This, to me, is the strategic leap that separates the early adopters from the laggards. It’s about understanding that advertising isn’t a series of isolated silos, but a connected ecosystem, and CTV is a powerful conductor in that orchestra.
Why Pharma is Still Stuck in Linear Time
So why the inertia? Is it just habit? Or is it a deeper fear of the unknown? The pharmaceutical industry, built on precision and rigorous testing, ironically seems hesitant to fully embrace the precise measurement and iterative optimization that CTV offers. Linear’s attribution challenges have been a long-standing frustration, yet brands persist. CTV offers the metrics that allow for real-time optimization – a concept that should resonate deeply with an industry that thrives on data-driven outcomes.
It’s like having a high-performance sports car but only driving it in first gear. The technology is there, the potential is immense, but the mindset hasn’t quite caught up. The eMarketer projection that U.S. CTV upfront ad spending will surpass primetime linear TV in 2026 is a stark reminder: the future isn’t coming, it’s already here. Brands that continue to relegate CTV to a supplementary role are not just missing out on immediate campaign gains; they’re potentially jeopardizing their long-term relevance in an increasingly digital-first healthcare landscape.
This isn’t just about better ad buys; it’s about fundamentally rethinking how brands connect with patients and healthcare professionals in the 21st century. The ‘halo effect’ isn’t a nice-to-have; it’s becoming a necessity for any brand that wants to truly understand and influence its audience across the entire media mix. CMI Media Group is out there, expanding its global reach, helping clients navigate this complex, exciting new frontier. The question is, will the rest of the industry follow suit before they’re left in the digital dust?
🧬 Related Insights
- Read more: Google Privacy Sandbox Explained: Topics API, Attribution Reporting, and More
- Read more: Yahoo DSP Ditches Hidden Fees to Win Commerce Media’s Trust Battle
Frequently Asked Questions
What is the ‘halo effect’ in CTV advertising?
The ‘halo effect’ refers to the positive impact a Connected TV advertising campaign has on other marketing channels, such as increased search volume, social media engagement, and overall brand awareness, which might not be directly attributed to the CTV ad itself.
Why are pharmaceutical brands slow to adopt CTV?
Pharmaceutical brands have historically relied on the established, albeit less flexible, linear TV model. Factors contributing to slow adoption may include ingrained habits, lengthy creative production cycles, and a perceived complexity in measuring and optimizing CTV campaigns compared to traditional methods.
How can pharma brands use CTV more effectively?
Pharma brands can use CTV more effectively by treating it as a strategic platform, not just a supplemental buy. This includes developing flexible creative assets, planning for the ‘halo effect’ by integrating CTV with other channels, and utilizing CTV’s advanced measurement capabilities for real-time optimization.
